Product Description
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Atosiban)
Mechanisms of Action: OXTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Austria | Bangladesh | Belgium | Bosnia | Brazil | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Obstetric Labor, Premature|Pregnancy Outcomes|Infertility
Phase 3: Obstetric Labor, Premature
Phase 2: Obstetric Labor, Premature|Endometriosis|Other
Phase 1: Vaginal Discharge|Pregnancy Outcomes|Heart Failure|Infertility|Heart Transplant|Tremor|Flushing|Stem Cell Transplant|Endometriosis|Headache|Dizziness|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07185230 |
NCT07185230 | N/A |
Not yet recruiting |
Infertility |
2027-06-30 |
2025-12-06 |
||
NCT06537778 |
sPTB | N/A |
Completed |
Obstetric Labor, Premature |
2024-02-12 |
2024-08-06 |
Primary Endpoints|Treatments |
|
NCT06399965 |
sPTB | N/A |
Withdrawn |
Obstetric Labor, Premature |
2024-02-12 |
2024-07-05 |
||
ChiCTR2200056942 |
ChiCTR2200056942 | N/A |
Not yet recruiting |
Unknown |
2023-12-31 |
|||
ChiCTR2000030175 |
ChiCTR2000030175 | N/A |
Not yet recruiting |
Obstetric Labor, Premature |
2021-12-30 |
|||
NCT03904745 |
Atosiban study | N/A |
Unknown status |
Infertility, Male|Infertility, Female |
2021-07-30 |
2022-12-03 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR1900022333 |
ChiCTR1900022333 | N/A |
Not yet recruiting |
Infertility |
2020-04-20 |
|||
NCT04468568 |
Atosiban Versus Terbutaline | N/A |
Completed |
Meningocele|Pregnancy Outcomes|Spina Bifida Cystica|Meningomyelocele |
2020-01-31 |
2022-06-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR1900020795 |
ChiCTR1900020795 | N/A |
Not yet recruiting |
Pregnancy Outcomes|Pregnancy, Ovarian |
2019-05-01 |
|||
NCT03570294 |
2015/I/17-GW | N/A |
Completed |
Obstetric Labor, Premature |
2018-06-10 |
2024-06-26 |
Primary Endpoints|Treatments |
|
ChiCTR-OOR-16008505 |
ChiCTR-OOR-16008505 | N/A |
Not yet recruiting |
Infertility |
2017-07-01 |
|||
NCT01493440 |
IVFAS1103 | N/A |
Completed |
Pregnancy Outcomes |
2011-08-01 |
2019-03-19 |
Treatments |
|
ChiCTR-IOQ-14005715 |
ChiCTR-IOQ-14005715 | N/A |
Completed |
Endometriosis |
None |
|||
NCT02893722 |
FERRING-001 | P1 |
Unknown status |
Heart Failure|Flushing|Tremor|Stem Cell Transplant|Heart Transplant|Endometriosis|Vaginal Discharge|Pregnancy Outcomes|Dizziness|Headache|Infertility |
2018-01-01 |
2019-03-20 |
Treatments |
|
NCT00679705 |
NCT00679705 | P1 |
Completed |
Healthy Volunteers |
2008-11-01 |
2025-08-27 |
||
NCT05382143 |
ENDOBAN | P2 |
Unknown status |
Endometriosis |
2022-06-01 |
2024-04-02 |
||
NCT01429545 |
NCT01429545 | P2 |
Completed |
Obstetric Labor, Premature |
2010-09-01 |
2019-03-19 |
Treatments |
|
NCT00587327 |
OVANCON | P2 |
Completed |
Other |
2008-05-01 |
2019-03-22 |
Treatments |
|
NCT02725736 |
755-15-TLV | P3 |
Unknown status |
Obstetric Labor, Premature |
2018-03-01 |
2019-03-20 |
Treatments |
|
2013-002561-19 |
Long term tokolysis with atosiban | P3 |
Terminated |
Obstetric Labor, Premature |
2015-11-30 |
2022-03-13 |
Treatments |
|
NCT01314859 |
MMC-NIF-2010-01 | P3 |
Withdrawn |
Obstetric Labor, Premature |
2012-07-01 |
2019-03-19 |
Treatments |
|
NCT05693688 |
APOSTEL 8 | P4 |
Completed |
Obstetric Labor, Premature |
2024-02-29 |
2024-07-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
2017-001007-72 |
APOSTEL VIII | P4 |
Active, not recruiting |
Obstetric Labor, Premature |
2023-06-21 |
2022-03-13 |
Treatments |
|
NCT01673399 |
NCT01673399 | P4 |
Completed |
Pregnancy Outcomes |
2015-02-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT01501214 |
HKUQMHCARE001 | P4 |
Completed |
Infertility |
2013-12-01 |
2023-06-28 |
Primary Endpoints|Treatments |